By Gwendolyn Wu
Published June 11, 2026
In a pivotal moment for both the Swiss pharmaceutical giant Novartis and the nascent field of RNA-based therapeutics, the company announced on Thursday that its experimental drug, delpacibart braxlosiran (del-brax), has achieved its primary biomarker endpoint in a Phase 1/2 clinical study. The drug, a cornerstone of Novartis’s massive $12 billion acquisition of Avidity Biosciences, is being developed to treat facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating muscle-wasting disease for which there are currently no approved disease-modifying therapies.
The success of the trial serves as an early but significant validation of Novartis’s strategic pivot toward genetic medicines. As the company navigates a shifting landscape in neuroscience and rare disease research, the positive readout provides a much-needed boost to its pipeline, suggesting that its high-stakes bet on antisense oligonucleotide conjugate (AOC) technology is beginning to pay dividends.
The Core Development: A Breakthrough in FSHD Treatment
Facioscapulohumeral muscular dystrophy is a progressive genetic disorder characterized by the wasting of muscles in the face, shoulder blades, and upper arms. It is caused by the aberrant expression of the DUX4 gene, which is typically silenced in healthy adult muscle tissue but becomes toxic when incorrectly activated in patients with FSHD. This toxicity leads to the progressive loss of muscle mass, chronic pain, and eventually, a severe decline in physical mobility.
Delpacibart braxlosiran—or "del-brax"—represents a novel approach to silencing this gene. As an antisense oligonucleotide conjugate, it is engineered to travel specifically to muscle tissue, where it binds to and degrades DUX4 mRNA, effectively preventing the production of the harmful protein. By addressing the root genetic cause of the disease rather than merely managing symptoms, del-brax offers the potential to arrest the progression of muscle damage.
The Phase 1/2 trial, which enrolled 90 participants, was designed to evaluate the safety, tolerability, and biological activity of the drug. By measuring changes in key biomarkers, investigators sought to determine if the drug could successfully penetrate muscle cells and exert its therapeutic effect.
Chronology: From Acquisition to Clinical Success
The path to this week’s milestone began in earnest last year when Novartis stunned the biotechnology sector by announcing its $12 billion acquisition of Avidity Biosciences. At the time, the deal was framed as a transformational move to secure a leading position in the development of RNA therapeutics.
- Mid-2025: Novartis finalizes the acquisition of Avidity Biosciences, integrating the company’s proprietary AOC platform into its global research and development infrastructure.
- Late 2025: The Phase 1/2 trial for del-brax undergoes rigorous monitoring as researchers analyze initial cohorts to establish optimal dosing regimens.
- Early 2026: Preliminary data from the study begins to circulate within the company, hinting at significant target engagement in muscle tissue.
- June 11, 2026: Novartis formally announces that the study has met its primary biomarker endpoint, confirming that the drug significantly lowered DUX4-regulated gene expression in patient muscle biopsies.
This progression highlights the accelerated nature of modern drug development, where advanced genetic modeling and precise molecular targeting allow companies to move from preclinical validation to human clinical milestones with increased confidence.
Supporting Data: Understanding the Impact of Del-Brax
The success of the study hinges on two primary biomarkers: the reduction of KHDC1L—a gene directly regulated by DUX4—and the suppression of creatine kinase, a long-established marker of muscle tissue breakdown.
According to the data released by Novartis, patients treated with del-brax showed a clear, dose-dependent reduction in these biomarkers compared to those in the placebo cohort. Specifically, the study evaluated three cohorts receiving varying doses of the drug. The results indicated that the therapy achieved "strong target engagement," meaning the AOC successfully reached the target tissue in sufficient concentrations to alter gene expression.
Furthermore, these findings align with earlier data previously disclosed by Avidity, which indicated that participants experienced tangible improvements in physical performance, including increased muscle strength and improved mobility. While the Phase 1/2 study focused heavily on biomarker data, the secondary clinical outcomes—such as the 10-meter walk/run test—provide a foundational basis for the upcoming Phase 3 trials.
Official Responses: Navigating the Path to Approval
The scientific and executive leadership at Novartis has expressed optimism regarding the results, viewing them as a clear signal that the drug is ready for broader testing.
"We are now evaluating the totality of the biomarker and clinical data and look forward to discussions with global regulatory agencies as we work with urgency to advance the development of del-brax for patients in need," said Nazem Atassi, Novartis’s global head of neuroscience and gene therapy development.
Atassi’s focus on "urgency" underscores the company’s intent to explore expedited regulatory pathways. Given the lack of existing treatments for FSHD, there is a strong argument for the drug to receive "fast-track" or "breakthrough therapy" designations from the FDA and other global regulators. Such designations could shorten the timeline for market access, potentially bringing the drug to patients years earlier than a standard approval process would allow.
Implications: The Strategic Landscape for Novartis
The market reaction to the announcement was swift, with Novartis shares rising nearly 3% in morning trading. This movement reflects investor confidence not only in the drug itself but in the broader "AOC" platform that Novartis inherited from Avidity.
Validation of the $12 Billion Bet
Industry analysts have been cautious regarding the massive price tag of the Avidity deal. However, Jefferies analyst Michael Leuchten noted that the trial results "at least partially validate Novartis’s decision to acquire Avidity." The data suggests that the technology is robust and capable of hitting biological targets in humans, which has historically been the primary hurdle for RNA-based therapies.
The Broader Pipeline
While del-brax is the current headline, the success of the platform has put a spotlight on the other two AOC candidates in the Novartis pipeline:
- Del-desiran: An experimental treatment for myotonic dystrophy. Data from this trial is expected in the second half of 2026, and it will be closely watched to see if the success of the FSHD trial can be replicated across different disease models.
- Del-zota: A mid-stage candidate for Duchenne muscular dystrophy (DMD). If this drug proves effective, it would significantly expand Novartis’s footprint in the neuromuscular space.
Looking Ahead: The Phase 3 Challenge
Novartis is already moving to the next stage, actively enrolling patients for a global Phase 3 trial. This study will be much larger and will shift from biomarker endpoints to functional clinical outcomes. Success in this trial will be the final hurdle before seeking commercial approval.
The company faces the complex challenge of balancing rapid development with the need to ensure the drug’s long-term safety profile. As the trial expands, Novartis will need to demonstrate that the sustained reduction of DUX4 is not only effective but also free of long-term side effects.
Ultimately, the June 11 announcement marks a transition from "experimental" to "promising" for Novartis’s genetic medicine division. For patients living with the daily challenges of FSHD, the news offers the first real hope for a treatment that targets the biological source of their condition. For Novartis, it represents the potential for a new era of dominance in the treatment of rare neuromuscular diseases, effectively justifying the significant capital deployed to acquire the technology that could redefine the company’s future.
About the Author
